Tacrolimus

cytochrome P450 family 2 subfamily C member 19 ; Homo sapiens







17 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35508605 The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients. 2022 May 4 6
2 32308538 Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. 2020 1
3 31096684 Impact of CYP3A5, POR, and CYP2C19 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplantation. 2019 May 15 3
4 31244435 Association of Genetic Variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with Tacrolimus Pharmacokinetics in Renal Transplant Recipients. 2019 1
5 26239045 Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. 2016 Apr 3
6 27191765 Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors. 2016 Aug 1
7 23175667 Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285. 2013 Feb 6
8 21883747 A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. 2012 Sep 2
9 21366650 Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. 2011 Apr 1
10 21802143 Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. 2011 Aug 2
11 23213600 Fatal lactic acidosis in a kidney transplant recipient on combination antiretroviral therapy after initiation of tacrolimus therapy. 2011 1
12 20596503 Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients. 2010 Jun 24 1
13 19139162 Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. 2009 Apr 3
14 17377957 Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. 2007 May 4
15 15010519 Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. 2004 May 3
16 15285851 Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. 2004 Aug 4
17 12431607 Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. 2002 Nov 1